<p>WAVE Life Sciences Ltd.（纳斯达克股票代码：WVE - 获取免费报告）在周三的交易中股价下跌了 7.6%。该公司股价最低曾达到 6.94 美元，最后交易价格为 6.9460 美元。在交易过程中，约有 883,299 股成交，较日均成交量 4,273,255 股下降了 79%。该股票此前收盘价为 7.52 美元。</p>
<p>获取 <strong>WAVE Life Sciences</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
<p>WVE 已成为多份研究分析师报告的主题。瑞穗证券在 3 月 25 日的研究报告中将 WAVE Life Sciences 的目标价从 22.00 美元上调至 27.00 美元，并给予该股票 “跑赢大盘” 的评级。Weiss Ratings 在 4 月 20 日的研究报告中重申了对 WAVE Life Sciences 的 “卖出（d-）” 评级。Wedbush 在 3 月 6 日的研究报告中将 WAVE Life Sciences 的目标价从 33.00 美元上调至 35.00 美元，并给予该股票 “跑赢大盘” 的评级。华尔街 Zen 在 4 月 12 日的研究报告中将 WAVE Life Sciences 的评级从 “卖出” 下调至 “强烈卖出”。最后，Cantor Fitzgerald 在 2 月 5 日的研究报告中将 WAVE Life Sciences 的目标价从 34.00 美元上调至 41.00 美元，并给予该股票 “增持” 的评级。十四位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，WAVE Life Sciences 目前的平均评级为 “适度买入”，共识目标价为 28.44 美元。</p>
<p><strong>阅读我们关于 WAVE Life Sciences 的最新报告</strong></p>
<h2>WAVE Life Sciences 股价下跌 6.4%</h2>
<ul>
<li>WAVE Life Sciences 因历史性 RNA 编辑成功而飙升 70%</li>
</ul>
<p>该公司的 50 日简单移动平均线为 10.28 美元，200 日简单移动平均线为 11.27 美元。该股票的市值为 13.2 亿美元，市盈率为-5.76，贝塔值为-1.32。</p>
<p>WAVE Life Sciences（纳斯达克股票代码：WVE - 获取免费报告）最近在 4 月 28 日发布了季度财报。该公司报告季度每股收益为（0.13 美元），超出市场共识预期的（0.34 美元）0.21 美元。该公司在本季度的收入为 3825 万美元，而市场共识预期为 845 万美元。WAVE Life Sciences 的股本回报率为-85.69%，净利润率为-478.35%。根据分析师的预测，WAVE Life Sciences Ltd.在当前年度的每股收益将为-1.39 美元。</p>
<h2>内部买卖情况</h2>
<ul>
<li>Sarepta Therapeutics Inc.：为何它是一颗冉冉升起的基因治疗明星</li>
</ul>
<p>在其他 WAVE Life Sciences 的新闻中，首席财务官 Kyle Moran 在 2 月 9 日的交易中出售了 3588 股该公司的股票。股票以平均价格 13.45 美元出售，总交易额为 48258.60 美元。出售完成后，首席财务官直接持有 134385 股该公司的股票，价值 1807478.25 美元。这代表其持股比例下降了 2.60%。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上查阅。此外，首席执行官 Paul Bolno 在 2 月 9 日的交易中出售了 10480 股该公司的股票。股票以平均价格 13.45 美元出售，总价值为 140956.00 美元。出售后，首席执行官直接持有 275520 股该公司的股票，价值约 3705744 美元。这代表其持股比例下降了 3.66%。该交易的披露信息可在 SEC 文件中找到。内部人士在上个季度出售了 52373 股公司股票，价值 757527 美元。目前 23.98% 的股票由内部人士持有。</p>
<h2>对 WAVE Life Sciences 的对冲基金看法</h2>
<p>几家机构投资者和对冲基金最近增加或减少了对该公司的投资。GSK plc 在第四季度获得了 WAVE Life Sciences 的新头寸，价值约 310,177,000 美元。Adage Capital Partners GP L.L.C.在第二季度将其在 WAVE Life Sciences 的持股增加了 20.0%。Adage Capital Partners GP L.L.C.目前持有 15016500 股该公司的股票，价值 97607000 美元，此前在该期间内又购买了 2500000 股。Price T Rowe Associates Inc. MD 在第四季度将其在 WAVE Life Sciences 的持股增加了 83.1%。Price T Rowe Associates Inc. MD 目前持有 7407372 股该公司的股票，价值 125927000 美元，此前在该期间内又购买了 3362880 股。Darwin Global Management Ltd.在第四季度获得了 WAVE Life Sciences 的新头寸，价值约 125168000 美元。最后，Federated Hermes Inc.在第四季度将其在 WAVE Life Sciences 的持股增加了 26.5%。Federated Hermes Inc.目前持有 4744520 股该公司的股票，价值 80657000 美元，此前在该期间内又购买了 993827 股。机构投资者和对冲基金持有该公司 89.73% 的股票。</p>
<h2>关于 WAVE Life Sciences</h2>
<p>（获取免费报告）</p>
<p>WAVE Life Sciences 是一家临床阶段的基因药物公司，专注于发现和开发立体纯度寡核苷酸疗法，旨在解决高未满足医疗需求的严重疾病。通过利用专有化学和精确合成，WAVE 设计具有明确立体化学的药物候选者，以优化效力、安全性和可制造性。这种方法旨在增强靶向特异性，并改善与传统寡核苷酸药物相比的治疗特性。</p>
<p>该公司的产品管线包括针对肌肉神经疾病（如杜氏肌营养不良症）和神经退行性疾病（如亨廷顿病）的项目，以及早期阶段的心血管和肝脏适应症。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 WAVE Life Sciences</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 WAVE 生命科学吗？</h2>
<p>在考虑 WAVE 生命科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 WAVE 生命科学并不在名单上。</p>
<p>虽然 WAVE 生命科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

WAVE生命科学

<p>WAVE 生命科学（NASDAQ:WVE）股价下跌 7.6%，至 6.9460 美元，交易量较平均水平下降 79%。分析师的看法不一，瑞穗证券将其目标价上调至 27 美元，而 Weiss Ratings 维持 “卖出” 评级。该公司报告的季度每股收益为（0.13 美元），超出预期，收入为 3825 万美元。公司内部人士进行了减持，首席财务官和首席执行官都减少了持股。机构投资者也调整了持股，GSK plc 获得了显著的股份</p>

<p>WAVE Life Sciences Ltd. (NASDAQ:WVE - Get Free Report) shares dropped 7.6% during trading on Wednesday . The company traded as low as $6.94 and last traded at $6.9460. Approximately 883,299 shares traded hands during trading, a decline of 79% from the average daily volume of 4,273,255 shares. The stock had previously closed at $7.52.</p>
<div class="lb-trans"><p>WAVE Life Sciences Ltd.（纳斯达克股票代码：WVE - 获取免费报告）在周三的交易中股价下跌了 7.6%。该公司股价最低曾达到 6.94 美元，最后交易价格为 6.9460 美元。在交易过程中，约有 883,299 股成交，较日均成交量 4,273,255 股下降了 79%。该股票此前收盘价为 7.52 美元。</p>
</div><p>Get <strong>WAVE Life Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>WAVE Life Sciences</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
</ul>
</div><p>WVE has been the topic of a number of research analyst reports. Mizuho lifted their target price on WAVE Life Sciences from $22.00 to $27.00 and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, March 25th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of WAVE Life Sciences in a research report on Monday, April 20th. Wedbush lifted their target price on WAVE Life Sciences from $33.00 to $35.00 and gave the stock an &#34;outperform&#34; rating in a research report on Friday, March 6th. Wall Street Zen cut WAVE Life Sciences from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a research report on Sunday, April 12th. Finally, Cantor Fitzgerald lifted their target price on WAVE Life Sciences from $34.00 to $41.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, February 5th. Fourteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, WAVE Life Sciences currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $28.44.</p>
<div class="lb-trans"><p>WVE 已成为多份研究分析师报告的主题。瑞穗证券在 3 月 25 日的研究报告中将 WAVE Life Sciences 的目标价从 22.00 美元上调至 27.00 美元，并给予该股票 “跑赢大盘” 的评级。Weiss Ratings 在 4 月 20 日的研究报告中重申了对 WAVE Life Sciences 的 “卖出（d-）” 评级。Wedbush 在 3 月 6 日的研究报告中将 WAVE Life Sciences 的目标价从 33.00 美元上调至 35.00 美元，并给予该股票 “跑赢大盘” 的评级。华尔街 Zen 在 4 月 12 日的研究报告中将 WAVE Life Sciences 的评级从 “卖出” 下调至 “强烈卖出”。最后，Cantor Fitzgerald 在 2 月 5 日的研究报告中将 WAVE Life Sciences 的目标价从 34.00 美元上调至 41.00 美元，并给予该股票 “增持” 的评级。十四位投资分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，WAVE Life Sciences 目前的平均评级为 “适度买入”，共识目标价为 28.44 美元。</p>
</div><p><strong>Read Our Latest Report on WAVE Life Sciences</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 WAVE Life Sciences 的最新报告</strong></p>
</div><h2>WAVE Life Sciences Trading Down 6.4%</h2>
<div class="lb-trans"><h2>WAVE Life Sciences 股价下跌 6.4%</h2>
</div><ul>
<li>Wave Life Sciences Rockets 70% on Historic RNA Editing Success</li>
</ul>
<div class="lb-trans"><ul>
<li>WAVE Life Sciences 因历史性 RNA 编辑成功而飙升 70%</li>
</ul>
</div><p>The company has a 50 day simple moving average of $10.28 and a 200 day simple moving average of $11.27. The stock has a market capitalization of $1.32 billion, a PE ratio of -5.76 and a beta of -1.32.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 10.28 美元，200 日简单移动平均线为 11.27 美元。该股票的市值为 13.2 亿美元，市盈率为-5.76，贝塔值为-1.32。</p>
</div><p>WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 28th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.21. The firm had revenue of $38.25 million during the quarter, compared to the consensus estimate of $8.45 million. WAVE Life Sciences had a negative return on equity of 85.69% and a negative net margin of 478.35%. On average, equities research analysts predict that WAVE Life Sciences Ltd. will post -1.39 EPS for the current year.</p>
<div class="lb-trans"><p>WAVE Life Sciences（纳斯达克股票代码：WVE - 获取免费报告）最近在 4 月 28 日发布了季度财报。该公司报告季度每股收益为（0.13 美元），超出市场共识预期的（0.34 美元）0.21 美元。该公司在本季度的收入为 3825 万美元，而市场共识预期为 845 万美元。WAVE Life Sciences 的股本回报率为-85.69%，净利润率为-478.35%。根据分析师的预测，WAVE Life Sciences Ltd.在当前年度的每股收益将为-1.39 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖情况</h2>
</div><ul>
<li>Sarepta Therapeutics Inc.: Why it's a rising gene therapy star</li>
</ul>
<div class="lb-trans"><ul>
<li>Sarepta Therapeutics Inc.：为何它是一颗冉冉升起的基因治疗明星</li>
</ul>
</div><p>In other WAVE Life Sciences news, CFO Kyle Moran sold 3,588 shares of the company's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $13.45, for a total transaction of $48,258.60. Following the completion of the sale, the chief financial officer directly owned 134,385 shares of the company's stock, valued at $1,807,478.25. This represents a 2.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CEO Paul Bolno sold 10,480 shares of the company's stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $140,956.00. Following the sale, the chief executive officer directly owned 275,520 shares of the company's stock, valued at approximately $3,705,744. This represents a 3.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 52,373 shares of company stock valued at $757,527 in the last quarter. 23.98% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他 WAVE Life Sciences 的新闻中，首席财务官 Kyle Moran 在 2 月 9 日的交易中出售了 3588 股该公司的股票。股票以平均价格 13.45 美元出售，总交易额为 48258.60 美元。出售完成后，首席财务官直接持有 134385 股该公司的股票，价值 1807478.25 美元。这代表其持股比例下降了 2.60%。该交易已在证券交易委员会的法律文件中披露，相关信息可在 SEC 网站上查阅。此外，首席执行官 Paul Bolno 在 2 月 9 日的交易中出售了 10480 股该公司的股票。股票以平均价格 13.45 美元出售，总价值为 140956.00 美元。出售后，首席执行官直接持有 275520 股该公司的股票，价值约 3705744 美元。这代表其持股比例下降了 3.66%。该交易的披露信息可在 SEC 文件中找到。内部人士在上个季度出售了 52373 股公司股票，价值 757527 美元。目前 23.98% 的股票由内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On WAVE Life Sciences</h2>
<div class="lb-trans"><h2>对 WAVE Life Sciences 的对冲基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. GSK plc acquired a new position in WAVE Life Sciences during the 4th quarter worth approximately $310,177,000. Adage Capital Partners GP L.L.C. increased its position in WAVE Life Sciences by 20.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company's stock worth $97,607,000 after purchasing an additional 2,500,000 shares during the period. Price T Rowe Associates Inc. MD increased its position in WAVE Life Sciences by 83.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,407,372 shares of the company's stock worth $125,927,000 after purchasing an additional 3,362,880 shares during the period. Darwin Global Management Ltd. acquired a new position in WAVE Life Sciences during the 4th quarter worth approximately $125,168,000. Finally, Federated Hermes Inc. increased its position in WAVE Life Sciences by 26.5% during the 4th quarter. Federated Hermes Inc. now owns 4,744,520 shares of the company's stock worth $80,657,000 after purchasing an additional 993,827 shares during the period. Institutional investors and hedge funds own 89.73% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近增加或减少了对该公司的投资。GSK plc 在第四季度获得了 WAVE Life Sciences 的新头寸，价值约 310,177,000 美元。Adage Capital Partners GP L.L.C.在第二季度将其在 WAVE Life Sciences 的持股增加了 20.0%。Adage Capital Partners GP L.L.C.目前持有 15016500 股该公司的股票，价值 97607000 美元，此前在该期间内又购买了 2500000 股。Price T Rowe Associates Inc. MD 在第四季度将其在 WAVE Life Sciences 的持股增加了 83.1%。Price T Rowe Associates Inc. MD 目前持有 7407372 股该公司的股票，价值 125927000 美元，此前在该期间内又购买了 3362880 股。Darwin Global Management Ltd.在第四季度获得了 WAVE Life Sciences 的新头寸，价值约 125168000 美元。最后，Federated Hermes Inc.在第四季度将其在 WAVE Life Sciences 的持股增加了 26.5%。Federated Hermes Inc.目前持有 4744520 股该公司的股票，价值 80657000 美元，此前在该期间内又购买了 993827 股。机构投资者和对冲基金持有该公司 89.73% 的股票。</p>
</div><h2>About WAVE Life Sciences</h2>
<div class="lb-trans"><h2>关于 WAVE Life Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.</p>
<div class="lb-trans"><p>WAVE Life Sciences 是一家临床阶段的基因药物公司，专注于发现和开发立体纯度寡核苷酸疗法，旨在解决高未满足医疗需求的严重疾病。通过利用专有化学和精确合成，WAVE 设计具有明确立体化学的药物候选者，以优化效力、安全性和可制造性。这种方法旨在增强靶向特异性，并改善与传统寡核苷酸药物相比的治疗特性。</p>
</div><p>The company's pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington's disease, as well as early-stage cardiovascular and liver indications.</p>
<div class="lb-trans"><p>该公司的产品管线包括针对肌肉神经疾病（如杜氏肌营养不良症）和神经退行性疾病（如亨廷顿病）的项目，以及早期阶段的心血管和肝脏适应症。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than WAVE Life Sciences</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 WAVE Life Sciences</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in WAVE Life Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 WAVE 生命科学吗？</h2>
</div><p>Before you consider WAVE Life Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 WAVE 生命科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and WAVE Life Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 WAVE 生命科学并不在名单上。</p>
</div><p>While WAVE Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 WAVE 生命科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

WAVE 生命科学（NASDAQ:WVE）股价下跌 7.6% - 以下是发生的事情